StemCell Institute Inc. (7096) Stock Price

Stemcell Research Institute operates a cell banking business focused on perinatal tissues such as "umbilical cord blood" and "umbilical cord tissue" for regenerative medicine and cell therapy purposes. The company develops new treatment methods and regenerative medicine products using these cells, and pursues business development and investment in the fields of regenerative medicine, infertility treatment, childbirth, and childcare.

Stemcell Research Institute's business consists of a single segment: the "cell banking business." Specifically, the company operates an "umbilical cord blood bank" that stores umbilical cord blood. It enters into "umbilical cord blood separation and storage consignment contracts" with customers (such as pregnant women), and collects, separates, and stores umbilical cord blood. The stored umbilical cord blood is preserved long-term at ultra-low temperatures for future medical treatment.

Umbilical cord blood contains "hematopoietic stem cells" that produce blood cells and "mesenchymal cells" that differentiate into nerve, cartilage, and cardiac muscle cells. These cells carry minimal cancer risk and can be used safely, making them potentially applicable to treatments for cerebral palsy and autism spectrum disorder. Stemcell Research Institute is conducting clinical research using these cells.

Stemcell Research Institute operates cell processing centers in Tokyo and Yokohama, where it performs umbilical cord blood separation, extraction, and preparation. These facilities are licensed under the Regenerative Medicine Safety Assurance Act and hold ISO 9001 and AABB certifications. The company also provides umbilical cord tissue storage services.

The company's revenue consists of three components: "processing fees," "storage fees," and "other." Processing fees cover cell separation and preparation costs, storage fees cover long-term cell preservation costs, and other fees include contract renewal charges. Through these operations, Stemcell Research Institute contributes to the advancement of regenerative medicine.

Stemcell Research Institute pursues innovative growth in regenerative medicine and cell therapy under the slogan "New choices in medical care for new lives." The company operates a cell banking business based on umbilical cord and cord blood, leveraging a strong network with obstetric and gynecological facilities, while focusing on developing new treatment methods and products.

The company aims to expand business scale by increasing the number of stored specimens annually. Specifically, it is promoting adoption of its new storage plan "HOPECELL" and strengthening marketing initiatives through both physical and online channels. The company also plans to enter Southeast Asian markets, with Singapore as a base for building revenue foundations.

In addition to deepening existing cord blood research, the company is collaborating with medical institutions engaged in regenerative medicine and cell therapy to explore new treatment protocols. Furthermore, it is pursuing expansion into promising fields through increased investment in related business areas and M&A activities.

As demand for cord blood storage grows with advances in regenerative medicine, Stemcell Research Institute is promoting clinical research both domestically and internationally. The company is also focusing on medical development using mesenchymal stem cells derived from umbilical cord and cultured cell supernatant, anticipating increased demand for storage services.

The company aims to increase inquiry requests and contract numbers through real-world marketing at obstetric facilities and optimization of online advertising. It is preparing to enter the Singapore market and planning phased expansion into major Southeast Asian countries. Through the launch of a regenerative medicine support program, the company seeks to expand opportunities for using stored cells.